首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1831659

免疫腫瘤學市場，規模，佔有率，趨勢，產業分析報告:治療方法，各新標的類型，各腫瘤或癌症類型，各地區，2025年～2034年的市場預測

Immuno-Oncology Market Size, Share, Trends, Industry Analysis Report By Treatment Approaches (Monoclonal Antibodies, Therapeutic Vaccines), By Novel Target Type, By Tumor or Cancer Type, By Region - Market Forecast, 2025-2034

出版日期: 2025年09月01日 | 出版商:

Polaris Market Research | 英文 128 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

根據 Polaris Market Research 的最新研究，預計到 2034 年，免疫腫瘤市場規模將達到 2,163.4 億美元。本報告深入分析了當前的市場動態，並對未來的市場成長進行了展望。

免疫腫瘤學被定義為一種先進的治療方法，它能夠增強人體免疫系統識別並精準對抗癌細胞的能力。推動該市場發展的因素是免疫療法聯合療法的快速普及。聯合療法整合了多種治療方法，旨在提高療效、克服抗藥性機制並產生更持久的臨床反應。由於分子生物學和免疫分析技術的進步，與單一療法相比，聯合療法能夠顯著改善患者的治療效果，因此正日益受到歡迎。

這些聯合療法的成功正在推動研究投資，並擴大其在多種癌症類型中的應用，從而鞏固其作為市場發展關鍵驅動力的地位。

免疫腫瘤學市場也受到日益重視生物標記驅動治療策略的影響，這些策略能夠開發高度標靶的個人化療法。透過利用基因突變、免疫特徵和腫瘤微環境特徵等生物標記物，臨床醫生可以更好地預測患者的治療反應並據此調整治療方案。這種精準治療方法能夠優化療效、最大限度地減少副作用並提高整體治療耐受性。此外，將生物標記研究整合到藥物研發流程中，正在加速技術創新，並推動免疫腫瘤學領域轉向更個人化的癌症治療方案。

免疫腫瘤市場報告亮點

依治療方法劃分，標靶PD-1/PD-L1和CTLA-4的免疫檢查點抑制劑預計將在2024年佔市場主導地位，收入佔有率達57.42%。

基於新型標靶類型，A2AR拮抗劑/CD73i療法預計在預測期內將以16.1%的複合年增長率增長，這主要得益於其抑制腫瘤中腺苷介導的免疫抑制的能力。

北美地區在先進的醫療保健系統和生物製藥創新中心的支持下，預計將在2024年佔全球31.27%的市場佔有率。

亞太地區免疫腫瘤市場預計到2034年將以16.3%的複合年增長率成長，這主要得益於治療可近性的提高和醫療保健投資的增加。

全球免疫腫瘤市場的主要參與者包括：安進公司；阿斯特捷利康；百時美施貴寶；禮來公司；葛蘭素史克公司；Incyte公司；強生生物技術公司；默克公司；諾華公司；輝瑞公司；羅氏控股公司；賽諾菲；以及武田製藥。

免疫腫瘤學(IO)-市場區隔和範圍
- 市場定義
免疫腫瘤學(IO)- 市場規模與成長預測
免疫腫瘤學(IO)-價值鏈分析
市場動態
- 促進因素
  - 非常規和先進治療技術的日益普及
  - 患有各種癌症的患者數量迅速增加
- 限制因素
  - 免疫療法的可及性和認知度較低
- 機會分析：免疫腫瘤學市場
  - 患者對改善癌症治療的需求不斷增長
波特五力分析
免疫腫瘤學 (IO) - 公司市佔率分析，2024 年
PEST 分析：免疫腫瘤學市場
塑造免疫腫瘤學的五大力量市場
COVID-19 影響分析

第5章免疫腫瘤學市場:治療方法估計·預測

治療各類型的市場規模
單株抗體
治療疫苗
查核點抑制劑
細胞激素

第6章免疫腫瘤學市場:各新標的類型估計·預測

各新標的類型市場規模
IDO1i
LAG-3 CPI
腫瘤溶解性病毒
STING促效劑
TLR促效劑
HDACi
TIL
VEGFi
VEGFi
VEGFi
VEGFi
GITR促效劑
TGF-b回水彎
A2AR拮抗劑/CD73i

第7章免疫腫瘤學市場:各腫瘤或癌症類型估計·預測

各腫瘤或癌症類型的市場規模
黑色素瘤
非小細胞肺癌
腎細胞癌症
頭頸椎癌症
膀胱癌
傳統何杰金氏淋巴瘤
merukeru細胞癌症
其他的癌症類型

第8章免疫腫瘤學市場:各地區估計·預測

各地區市場規模
北美
- 美國
- 加拿大
歐洲
- 法國
- 德國
- 義大利
- 西班牙
- 英國
- 奧地利
- 荷蘭
- EU的殘餘
亞太地區
- 中國
- 印度
- 日本
- 印尼
- 韓國
- 馬來西亞
- 亞太地區
南美
- 巴西
- 墨西哥
- 阿根廷
- 其他的南美各國
中東·非洲
- 以色列
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 其他中東和非洲

第9章競爭情形

策略性架構
COVID-19大流行病中主要企業採用了的策略
競爭環境
合併·收購分析

第10章企業簡介

Bristol Myers Squibb
Merck & Co.
AstraZeneca
Roche Holding AG
Pfizer Inc.
Incyte Corporation
Amgen, Inc.
Eli Lilly and Company
GlaxoSmithKline Plc
Janssen Biotech, Inc
Novartis AG
Sanofi
Takeda Pharmaceuticals

簡介目錄圖表

Product Code: PM1083

The Immuno-oncology market size is expected to reach USD 216.34 billion by 2034, according to a new study by Polaris Market Research. The report "Immuno-Oncology Market Share, Size, Trends, Industry Analysis Report By Treatment Approaches (Monoclonal Antibodies, Therapeutic Vaccines), By Novel Target Type, By Tumor or Cancer Type, By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Immuno-oncology can be defined as an advanced therapeutic approach that empowers the body's immune system to recognize and combat cancer cells with precision. This market is driven by the rapid adoption of combination immunotherapies, which integrate multiple treatment modalities to enhance efficacy, overcome resistance mechanisms, and provide more durable clinical responses. These approaches are gaining traction as they deliver improved patient outcomes compared to monotherapies, supported by ongoing advancements in molecular biology and immune profiling. The increasing success of such combinations is driving research investment and expanding the scope of application across various cancer types, reinforcing their role as a cornerstone of the market's evolution.

The immuno-oncology market is further influenced by the growing focus on biomarker-driven treatment strategies, enabling the development of highly targeted and personalized therapies. Clinicians can better predict patient response and tailor treatments accordingly by leveraging biomarkers such as genetic mutations, immune signatures, and tumor microenvironment characteristics. This precision-focused approach optimizes therapeutic effectiveness and also minimizes adverse effects, improving overall treatment tolerability. Additionally, the integration of biomarker research into drug development pipelines is accelerating innovation and enabling a shift toward more individualized cancer care solutions within the immuno-oncology landscape.

Immuno-Oncology Market Report Highlights

In terms of treatment approaches, the checkpoint inhibitors led with 57.42% revenue share in 2024, driven by their durable clinical responses across cancers through PD-1/PD-L1 and CTLA-4 targeting.

Based on novel target type, the A2AR antagonist/CD73i therapies segment is expected to register the highest CAGR of 16.1% during the forecast period by disrupting adenosine-mediated immunosuppression in tumors.

In 2024, North America dominated with 31.27% global share, supported by advanced healthcare systems and biopharma innovation hubs.

The Asia Pacific Immuno-Oncology Market would report a CAGR of 16.3% by 2034, fueled by rising treatment access and healthcare investments.

A few global key Immuno-Oncology Market players include Amgen, Inc.; AstraZeneca; Bristol Myers Squibb; Eli Lilly and Company; GlaxoSmithKline Plc; Incyte Corporation; Janssen Biotech, Inc; Merck & Co.; Novartis AG; Pfizer Inc.; Roche Holding AG; Sanofi; and Takeda Pharmaceuticals.

Polaris Market Research has segmented the Immuno-Oncology Market report on the basis of treatment approaches, novel target type, tumor or cancer type, and region:

By Treatment Approaches Outlook (Revenue, USD Billion, 2020-2034)

Monoclonal Antibodies

Therapeutic Vaccines

Checkpoint Inhibitors

Cytokines

By Novel Target Type Outlook (Revenue, USD Billion, 2020-2034)

IDO1i

LAG-3 CPI

Oncolytic Virus

STING Agonist

TLR Agonist

HDACi

TIL

VEGFi

MEKi

TIGIT

CPI

GITR Agonist

TGF-b trap

A2AR Antagonist/CD73i

By Tumor or Cancer Type Outlook (Revenue, USD Billion, 2020-2034)

Melanoma

Non-Small Cell Lung Cancer

Renal Cell Carcinoma

Head, Face & Neck Cancer

Bladder Cancer

Classical Hodgkin's Lymphoma

Merkel Cell Carcinoma

Other Cancer Types

By Regional Outlook (Revenue, USD Billion, 2020-2034)

North America

U.S.

Canada

Europe

Germany

France

Italy

Spain

Russia

Netherlands

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Vietnam

Australia

Rest of Asia Pacific

Latin America

Argentina

Brazil

Mexico

Rest of Latin America

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Rest of Middle East & Africa

Chapter 1. Introduction

1.1 Report Description

Chapter 2. Research Methodology Overview

2.1 Research Process
- 2.1.1 Information procurement
- 2.1.2 Purchased database:
- 2.1.3 Polaris Market Research's internal database
2.2 Research Methodology
2.3 Research Scope & Assumptions
2.4 List of Data Sources

Chapter 3. Executive Summary

3.1 Market Snapshot - Key Takeaways
3.2 Immuno-Oncology (IO) regional market place: Key takeaways

Chapter 4. Immuno-Oncology (IO) Market Insights

4.1 Immuno-Oncology (IO) - Market segmentation & scope
- 4.1.1 Market definitions
4.2 Immuno-Oncology (IO) - Market size and growth prospects
4.3 Immuno-Oncology (IO) - Value chain analysis
4.4 Market Dynamics
- 4.4.1 Drivers
  - 4.4.1.1 Increasing introduction of unconventional and advanced treatment techniques
  - 4.4.1.2 Rapidly growing population of various cancer infected patients
- 4.4.2 Restraints
  - 4.4.2.1 Limited access and awareness about immunotherapy
- 4.4.3 Opportunity analysis: Immunology-oncology market
  - 4.4.3.1 Increasing demand for improved cancer care by patients
4.5 Porter's Five Forces Analysis
4.6 Immuno-Oncology (IO) - Company Market Share Analysis, 2024
4.7 PEST Analysis: Immuno-Oncology Market
4.8 Five forces shaping the immuno-oncology market
4.9 COVID-19 Impact Analysis

Chapter 5. Immuno-Oncology Market Estimates and Forecast, by Treatment Approaches

5.1 Market size by treatment type
5.2 Monoclonal Antibodies
- 5.2.1 Global Immuno-Oncology monoclonal antibodies treatment market estimates & forecasts by region, 2021-2034
5.3 Therapeutic Vaccines
- 5.3.1 Global Immuno-Oncology therapeutic vaccines treatment market estimates & forecasts by region, 2021-2034
5.4 Checkpoint Inhibitors
- 5.4.1 Global Immuno-Oncology checkpoint inhibitors treatment market estimates & forecasts by region, 2021-2034
5.5 Cytokines
- 5.5.1 Global Immuno-Oncology cytokines treatment market estimates & forecasts by region, 2021-2034

Chapter 6. Immuno-Oncology Market Estimates and Forecast, by Novel Target Type

6.1 Market size by novel target type
6.2 IDO1i
- 6.2.1 Global Immuno-Oncology market estimates & forecasts for IDO1i target by region, 2021-2034
6.3 LAG-3 CPI
- 6.3.1 Global Immuno-Oncology market estimates & forecasts for LAG-3 CPI target by region, 2021-2034
6.4 Oncolytic virus
- 6.4.1 Global Immuno-Oncology market estimates & forecasts for Oncolytic virus target by region, 2021-2034
6.5 STING agonist
- 6.5.1 Global Immuno-Oncology market estimates & forecasts for STING agonist target by region, 2021-2034
6.6 TLR agonist
- 6.6.1 Global Immuno-Oncology market estimates & forecasts for TLR agonist target by region, 2021-2034
6.7 HDACi
- 6.7.1 Global Immuno-Oncology market estimates & forecasts for HDACi target by region, 2021-2034
6.8 TIL
- 6.8.1 Global Immuno-Oncology market estimates & forecasts for TIL target by region, 2021-2034
6.9 VEGFi
- 6.9.1 Global Immuno-Oncology market estimates & forecasts for VEGFi target by region, 2021-2034
6.10 MEKi
- 6.10.1 Global Immuno-Oncology market estimates & forecasts for MEKi target by region, 2021-2034
6.11 TIGIT
- 6.11.1 Global Immuno-Oncology market estimates & forecasts for TIGIT target by region, 2021-2034
6.12 CPI
- 6.12.1 Global Immuno-Oncology market estimates & forecasts for CPI target by region, 2021-2034
6.13 GITR agonist
- 6.13.1 Global Immuno-Oncology market estimates & forecasts for GITR agonist target by region, 2021-2034
6.14 TGF-b trap
- 6.14.1 Global Immuno-Oncology market estimates & forecasts for TGF-b trap target by region, 2021-2034
6.15 A2AR antagonist/CD73i
- 6.15.1 Global Immuno-Oncology market estimates & forecasts for A2AR antagonist/CD73i target by region, 2021-2034

Chapter 7. Immuno-Oncology Market Estimates and Forecast, by Tumor or Cancer Type

7.1 Market size by tumor or cancer type
7.2 Melanoma
- 7.2.1 Global Immuno-Oncology market estimates & forecasts for melanoma cancer by region, 2021-2034
7.3 Non-small cell lung cancer
- 7.3.1 Global Immuno-Oncology market estimates & forecasts for non-small cell lung cancer by region, 2021-2034
7.4 Renal cell carcinoma
- 7.4.1 Global Immuno-Oncology market estimates & forecasts for renal cell carcinoma cancer by region, 2021-2034
7.5 Head, face & neck cancer
- 7.5.1 Global Immuno-Oncology market estimates & forecasts for head, face & neck cancer by region, 2021-2034
7.6 Bladder cancer
- 7.6.1 Global Immuno-Oncology market estimates & forecasts for bladder cancer by region, 2021-2034
7.7 Classical hodgkin's lymphoma
- 7.7.1 Global Immuno-Oncology market estimates & forecasts for classical hodgkin's lymphoma cancer by region, 2021-2034
7.8 Merkel cell carcinoma
- 7.8.1 Global Immuno-Oncology market estimates & forecasts for merkel cell carcinoma cancer by region, 2021-2034
7.9 Other cancer types
- 7.9.1 Global Immuno-Oncology market estimates & forecasts for other cancer types by region, 2021-2034

Chapter 8. Immuno-Oncology Market Estimates and Forecast, by Region

8.1 Market size by region
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 France
- 8.3.2 Germany
- 8.3.3 Italy
- 8.3.4 Spain
- 8.3.5 UK
- 8.3.6 Austria
- 8.3.7 Netherlands
- 8.3.8 Rest of EU
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 India
- 8.4.3 Japan
- 8.4.4 Indonesia
- 8.4.5 South Korea
- 8.4.6 Malaysia
- 8.4.7 RoAPAC
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of LATAM
8.6 Middle East & Africa
- 8.6.1 Israel
- 8.6.2 Saudi Arabia
- 8.6.3 South Africa
- 8.6.4 UAE
- 8.6.5 Rest of Middle East & Africa

Chapter 9. Competitive Landscape

9.1 Strategy framework
9.2 Strategies Adopted By Major Players During COVID-19 Pandemic
9.3 Competitive Environment
9.4 Merger & Acquisition Analysis

Chapter 10. Company Profiles

10.1 Bristol Myers Squibb
- 10.1.1 Company Overview
- 10.1.2 Financial Performance (Revenue)
- 10.1.3 Product Benchmarking
- 10.1.4 Recent Developments
10.2 Merck & Co.
- 10.2.1 Company Overview
- 10.2.2 Financial Performance (Revenue)
- 10.2.3 Product Benchmarking
- 10.2.4 Recent Developments
10.3 AstraZeneca
- 10.3.1 Company Overview
- 10.3.2 Financial Performance (Revenue)
- 10.3.3 Product Benchmarking
- 10.3.4 Recent Developments
10.4 Roche Holding AG
- 10.4.1 Company Overview
- 10.4.2 Financial Performance (Revenue)
- 10.4.3 Product Benchmarking
- 10.4.4 Recent Developments
10.5 Pfizer Inc.
- 10.5.1 Company Overview
- 10.5.2 Financial Performance (Revenue)
- 10.5.3 Product Benchmarking
- 10.5.4 Recent Developments
10.6 Incyte Corporation
- 10.6.1 Company Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Benchmarking
- 10.6.4 Recent Developments
10.7 Amgen, Inc.
- 10.7.1 Company Overview
- 10.7.2 Financial Performance (Revenue)
- 10.7.3 Product Benchmarking
- 10.7.4 Recent Developments
10.8 Eli Lilly and Company
- 10.8.1 Company Overview
- 10.8.2 Financial Performance (Revenue)
- 10.8.3 Product Benchmarking
- 10.8.4 Recent Developments
10.9 GlaxoSmithKline Plc
- 10.9.1 Company Overview
- 10.9.2 Financial Performance (Revenue)
- 10.9.3 Product Benchmarking
- 10.9.4 Recent Developments
10.10 Janssen Biotech, Inc
- 10.10.1 Company Overview
- 10.10.2 Jonson & Johnson Financial Performance (Revenue)
- 10.10.3 Product Benchmarking
- 10.10.4 Recent Developments
10.11 Novartis AG
- 10.11.1 Company Overview
- 10.11.2 Financial Performance (Revenue)
- 10.11.3 Product Benchmarking
- 10.11.4 Recent Developments
10.12 Sanofi
- 10.12.1 Company Overview
- 10.12.2 Financial Performance (Revenue)
- 10.12.3 Product Benchmarking
- 10.12.4 Recent Developments
10.13 Takeda Pharmaceuticals
- 10.13.1 Company Overview
- 10.13.2 Financial Performance (Revenue)
- 10.13.3 Product Benchmarking
- 10.13.4 Recent Developments

簡介目錄圖表

List of Tables

Table 1 Global Immuno-Oncology market estimates & forecasts by region, 2021-2034, (USD Billion)
Table 2 Drivers and inhibitors for global immuno-oncology market:
Table 3 Restraints for global immuno-oncology market:
Table 4 Global Immuno-Oncology monoclonal antibodies treatment market estimates & forecasts by region, 2021-2034, (USD Billion)
Table 5 Global Immuno-Oncology therapeutic vaccines treatment market estimates & forecasts by region, 2021-2034, (USD Billion)
Table 6 Global Immuno-Oncology checkpoint inhibitors treatment market estimates & forecasts by region, 2021-2034, (USD Billion)
Table 7 Global Immuno-Oncology cytokines treatment market estimates & forecasts by region, 2021-2034, (USD Billion)
Table 8 Global Immuno-Oncology market estimates & forecasts for IDO1i target by region, 2021-2034, (USD Billion)
Table 9 Global Immuno-Oncology market estimates & forecasts for LAG-3 CPI target by region, 2021-2034, (USD Billion)
Table 10 Global Immuno-Oncology market estimates & forecasts for Oncolytic virus target by region, 2021-2034, (USD Billion)
Table 11 Global Immuno-Oncology market estimates & forecasts for STING agonist target by region, 2021-2034, (USD Billion)
Table 12 Global Immuno-Oncology market estimates & forecasts for TLR agonist target by region, 2021-2034, (USD Billion)
Table 13 Global Immuno-Oncology market estimates & forecasts for HDACi target by region, 2021-2034, (USD Billion)
Table 14 Global Immuno-Oncology market estimates & forecasts for TIL target by region, 2021-2034, (USD Billion)
Table 15 Global Immuno-Oncology market estimates & forecasts for VEGFi target by region, 2021-2034, (USD Billion)
Table 16 Global Immuno-Oncology market estimates & forecasts for MEKi target by region, 2021-2034, (USD Billion)
Table 17 Global Immuno-Oncology market estimates & forecasts for TIGIT target by region, 2021-2034, (USD Billion)
Table 18 Global Immuno-Oncology market estimates & forecasts for CPI target by region, 2021-2034, (USD Billion)
Table 19 Global Immuno-Oncology market estimates & forecasts for GITR agonist target by region, 2021-2034, (USD Billion)
Table 20 Global Immuno-Oncology market estimates & forecasts for TGF-b trap target by region, 2021-2034, (USD Billion)
Table 21 Global Immuno-Oncology market estimates & forecasts for A2AR antagonist/CD73i target by region, 2021-2034, (USD Billion)
Table 22 Global Immuno-Oncology market estimates & forecasts for melanoma cancer by region, 2021-2034, (USD Billion)
Table 23 Global Immuno-Oncology market estimates & forecasts for non-small cell lung cancer by region, 2021-2034, (USD Billion)
Table 24 Global Immuno-Oncology market estimates & forecasts for renal cell carcinoma cancer by region, 2021-2034, (USD Billion)
Table 25 Global Immuno-Oncology market estimates & forecasts for head, face & neck cancer by region, 2021-2034, (USD Billion)
Table 26 Global Immuno-Oncology market estimates & forecasts for bladder cancer by region, 2021-2034, (USD Billion)
Table 27 Global Immuno-Oncology market estimates & forecasts for classical hodgkin's lymphoma cancer by region, 2021-2034, (USD Billion)
Table 28 Global Immuno-Oncology market estimates & forecasts for merkel cell carcinoma cancer by region, 2021-2034, (USD Billion)
Table 29 Global Immuno-Oncology market estimates & forecasts for other cancer types by region, 2021-2034, (USD Billion)
Table 30 North America Immuno-Oncology market estimates & forecasts by Country, 2021-2034, (USD Billion)
Table 31 North America Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 32 North America Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 33 North America Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 34 U.S. Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 35 U.S. Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 36 U.S. Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 37 Canada Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 38 Canada Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 39 Canada Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 40 Europe Immuno-Oncology market estimates & forecasts by Country, 2021-2034, (USD Billion)
Table 41 Europe Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 42 Europe Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 43 Europe Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 44 France Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 45 France Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 46 France Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 47 Germany Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 48 Germany Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 49 Germany Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 50 Italy Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 51 Italy Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 52 Italy Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 53 Spain Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 54 Spain Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 55 Spain Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 56 UK Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 57 UK Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 58 UK Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 59 Austria Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 60 Austria Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 61 Austria Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 62 Netherlands Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 63 Netherlands Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 64 Netherlands Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 65 Rest of EU Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 66 Rest of EU Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 67 Rest of EU Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 68 Asia Pacific Immuno-Oncology market estimates & forecasts by Country, 2021-2034, (USD Billion)
Table 69 Asia Pacific Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 70 Asia Pacific Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 71 Asia Pacific Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 72 China Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 73 China Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 74 China Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 75 India Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 76 India Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 77 India Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 78 Japan Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 79 Japan Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 80 Japan Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 81 Indonesia Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 82 Indonesia Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 83 Indonesia Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 84 South Korea Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 85 South Korea Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 86 South Korea Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 87 Malaysia Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 88 Malaysia Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 89 Malaysia Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 90 RoAPAC Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 91 RoAPAC Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 92 RoAPAC Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 93 Latin America Immuno-Oncology market estimates & forecasts by Country, 2021-2034, (USD Billion)
Table 94 Latin America Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 95 Latin America Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 96 Latin America Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 97 Brazil Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 98 Brazil Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 99 Brazil Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 100 Mexico Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 101 Mexico Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 102 Mexico Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 103 Argentina Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 104 Argentina Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 105 Argentina Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 106 Rest of LATAM Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 107 Rest of LATAM Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 108 Rest of LATAM Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 109 Middle East & Africa Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 110 Middle East & Africa Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 111 Middle East & Africa Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 112 Middle East & Africa Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 113 Israel Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 114 Israel Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 115 Israel Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 116 Saudi Arabia Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 117 Saudi Arabia Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 118 Saudi Arabia Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 119 South Africa Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 120 South Africa Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 121 South Africa Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 122 UAE Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 123 UAE Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 124 UAE Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 125 RoMEA Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 126 RoMEA Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 127 RoMEA Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)